MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$1,407,259
EPS
-$0.03
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
General and administrative
778,908
700,898
238,740.5
701,170
Research and development
600,000
400,000
-
-
Total operating expenses
1,378,908
1,100,898
238,740.5
701,170
Loss from operations
-1,378,908
-1,100,898
-238,740.5*
-701,170
Interest expense, related parties
18,844
18,638
93,893*
19,052
Interest income
-
-
3,440*
-
Interest and other income
8,223
-
-
-
Forgiveness of unrelated vendor payables
11,515
-
-9,164,574*
-
Change in fair value of deferred underwriting fee - paid in common stock
-
-
98,000*
560,000
Change in the fair value of warrant liabilities
29,245
4,178
-114,346.5*
-76,871
Gain on exchange of common stock for warrants
-
-
3,480,000*
-1,740,000
Fair value of common stock to be issued for contingent liability
-
-
1,840,000*
-
Total other income (expense), net
-28,351
-22,816
-7,402,680.5*
-1,122,181
Net income (loss)
-1,407,259
-1,123,714
-7,641,421
-1,823,351
Basic EPS
-0.03
-0.03
-0.365
-0.07
Diluted EPS
-0.03
-0.03
-0.365
-0.07
Basic Average Shares
48,398,314
35,999,589
20,951,937
27,007,568
Diluted Average Shares
48,398,314
35,999,589
20,951,937
27,007,568
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net income (loss)
-$1,407,259
(-1342.21%↓ Y/Y)
Loss from operations
-$1,378,908
(-23.31%↓ Y/Y)
Total other income
(expense), net
-$28,351
(-102.30%↓ Y/Y)
Forgiveness of unrelated
vendor payables
$11,515
(-99.46%↓ Y/Y)
Interest and other income
$8,223
Total operating
expenses
$1,378,908
(23.31%↑ Y/Y)
Change in the fair value
of warrant...
$29,245
(-74.98%↓ Y/Y)
Interest expense,
related parties
$18,844
(-69.75%↓ Y/Y)
General and
administrative
$778,908
(-30.34%↓ Y/Y)
Research and development
$600,000
Buy us a coffee
Liminatus Pharma, Inc. (LIMN)
Liminatus Pharma, Inc. (LIMN)